supported by the National Natural Science Foundation of China(22177022,22267005);the Natural Science Foundation of Guangxi Province of China(AD22035193).
The development of anticancer drugs to treat triple-negative breast cancer(TNBC)is an ongoing challenge.Immunogenic cell death(ICD)has garnered considerable interest worldwide as a promising synergistic modality for c...